AZTA Stock Analysis: Azenta | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.794m USD | 12M Return: 33.8% | US1143401024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.9M
EPS Trend: 74.9%
Qual. Beats: 0
Rev. Trend: -46.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Azenta, Inc. (NASDAQ: AZTA) is a provider of biological and chemical compound sample exploration and management solutions for the global life sciences industry, with operations spanning the United States, China, the United Kingdom, rest of Europe, and the Asia Pacific. The company operates through two reportable segments: Sample Management Solutions, which offers automated storage systems, cryogenic equipment, consumables, and sample repository services, and Multiomics, which provides genomic analysis services including gene sequencing and gene synthesis.
Azenta also maintains a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space, reflecting an emerging trend of off-Earth research within the life sciences sector. The life sciences tools and services industry is characterized by demand from pharmaceutical, biotechnology, and academic research customers who rely on specialized storage and analytical infrastructure to preserve and analyze biological samples.
Originally founded in 1978 and headquartered in Burlington, Massachusetts, the company was previously known as Brooks Automation, Inc. before rebranding to Azenta, Inc. in December 2021, a transition that aligned its corporate identity more closely with its life sciences-focused operations following the divestiture of its legacy semiconductor automation business.
- Biopharma R&D budgets drive Sample Management Solutions segment revenue
- Multiomics margins compress amid gene sequencing competition
- China exposure weighs on international sample storage revenue
| Net Income: -122.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -1.74 > 1.0 |
| NWC/Revenue: 66.60% < 20% (prev 73.97%; Δ -7.38% < -1%) |
| CFO/TA 0.02 > 3% & CFO 38.0m > Net Income -122.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.3m) vs 12m ago -0.93% < -2% |
| Gross Margin: 44.05% > 18% (prev 46.28%; Δ -2.24% > 0.5%) |
| Asset Turnover: 31.51% > 50% (prev 28.99%; Δ 2.52% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.22 (Total Current Assets 681.4m - Total Current Liabilities 272.6m) / Total Assets 1.88b |
| B: 0.66 (Retained Earnings 1.25b / Total Assets 1.88b) |
| C: -0.08 (EBIT TTM -152.3m / Avg Total Assets 1.95b) |
| D: 4.13 (Book Value of Equity 1.51b / Total Liabilities 366.1m) |
| Altman-Z'' = 7.40 = AAA |
| DSRI: 1.10 (Receivables 143.7m/124.5m, Revenue 613.8m/585.4m) |
| GMI: 1.05 (GM 46.28% / 44.05%) |
| AQI: 0.92 (AQ_t 0.51 / AQ_t-1 0.56) |
| SGI: 1.05 (Revenue 613.8m / 585.4m) |
| TATA: -0.09 (NI -122.9m - CFO 38.0m) / TA 1.88b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of November 11, 2026, the stock is trading at USD 40.48 with a total of 675,893 shares traded. Over the past week, the price has changed by +8.99%, over one month by +7.18%, over three months by +21.45% and over the past year by +33.77%.
Current recommended Stop Loss: 37.80 (which is 6.6% or 1.2 ATR below the current price).
Azenta has received a consensus analysts rating of 3.83. Therefore, it is recommended to buy AZTA.
- StrongBuy: 2
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 37.8 | -6.6% |
P/E Forward = 29.0698
P/S = 2.9227
P/B = 1.136
P/EG = 0.5263
Revenue TTM = 613.8m USD
EBIT TTM = -152.3m USD
EBITDA TTM = -96.6m USD
Long Term Debt = unknown (none)
Short Term Debt = 7.78m USD (from shortTermDebt, last fiscal year)
Debt = 54.0m USD (from shortLongTermDebtTotal, last quarter) (leases 54.0m already included)
Net Debt = -271.8m USD (calculated: Debt 54.0m - CCE 325.8m)
Enterprise Value = 1.52b USD (1.79b + Debt 54.0m - CCE 325.8m)
Interest Coverage Ratio = unknown (Ebit TTM -152.3m / Interest Expense TTM 0.0)
EV/FCF = 154.0x (Enterprise Value 1.52b / FCF TTM 9.88m)
FCF Yield = 0.65% (FCF TTM 9.88m / Enterprise Value 1.52b)
FCF Margin = 1.61% (FCF TTM 9.88m / Revenue TTM 613.8m)
Net Margin = -20.02% (Net Income TTM -122.9m / Revenue TTM 613.8m)
Gross Margin = 44.05% ((Revenue TTM 613.8m - Cost of Revenue TTM 343.4m) / Revenue TTM)
Gross Margin QoQ = 44.89% (prev 42.84%)
Tobins Q-Ratio = 0.81 (Enterprise Value 1.52b / Total Assets 1.88b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 54.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -120.3m (EBIT -152.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.50 (Total Current Assets 681.4m / Total Current Liabilities 272.6m)
Debt / Equity = 0.04 (Debt 54.0m / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = 2.81 (negative EBITDA) (Net Debt -271.8m / EBITDA -96.6m)
Debt / FCF = -27.51 (Net Debt -271.8m / FCF TTM 9.88m)
Total Stockholder Equity = 1.63b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.31% (Net Income -122.9m / Total Assets 1.88b)
RoE = -7.56% (Net Income TTM -122.9m / Total Stockholder Equity 1.63b)
RoCE = -9.49% (EBIT -152.3m / Capital Employed (Total Assets 1.88b - Current Liab 272.6m))
RoIC = -7.61% (negative operating profit) (NOPAT -120.3m / Invested Capital 1.58b)
WACC = 10.50% (E(1.79b)/V(1.85b) * Re(10.82%) + D(54.0m)/V(1.85b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.36 | Cagr: -8.60%
[DCF] Terminal Value 65.50% ; FCFF base≈24.2m ; Y1≈21.2m ; Y5≈17.1m
[DCF] Fair Price = 10.85 (EV 203.4m - Net Debt -271.8m = Equity 475.3m / Shares 43.8m; r=10.50% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 74.90 | EPS CAGR: 24.05% | SUE: 0.71 | # QB: 0
Revenue Correlation: -46.54 | Revenue CAGR: -2.11% | SUE: 0.41 | # QB: 0
EPS current Quarter (2026-12-31): EPS=0.10 | Chg30d=-22.64% | Revisions=-25% | Analysts=3
EPS current Year (2026-09-30): EPS=0.32 | Chg30d=-9.06% | Revisions=-40% | GrowthEPS=-37.6% | GrowthRev=+3.5%
EPS next Year (2027-09-30): EPS=0.53 | Chg30d=-10.47% | Revisions=-25% | GrowthEPS=+65.2% | GrowthRev=+4.0%
[Analyst] Revisions Ratio: -57% (up=0, down=4)